Target type: biologicalprocess
The directed movement of triglyceride into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Triglycerides are important components of plant oils, animal fats and animal plasma lipoproteins. [GOC:BHF, GOC:rl]
Triglycerides (TGs) are the primary form of energy storage in the body. They are synthesized in the liver and small intestine and transported in the blood via lipoproteins, specifically very-low-density lipoproteins (VLDL). The process of TG transport can be broken down into the following steps:
1. **Synthesis and Packaging:** In the liver, fatty acids from dietary sources or de novo synthesis are combined with glycerol to form TGs. These TGs are then packaged into VLDL particles along with cholesterol, phospholipids, and apolipoproteins. Apolipoproteins are proteins that act as ligands for specific receptors on cells and play a crucial role in lipoprotein metabolism.
2. **Secretion from the Liver:** VLDL particles are secreted from the liver into the bloodstream. Once in the circulation, VLDL undergoes a series of modifications.
3. **Lipoprotein Lipase (LPL) Activity:** VLDL particles encounter lipoprotein lipase (LPL), an enzyme that resides on the surface of endothelial cells lining blood vessels. LPL hydrolyzes TGs in VLDL, releasing free fatty acids and glycerol. These products can then be taken up by tissues for energy production or re-esterification.
4. **Formation of Intermediate Density Lipoproteins (IDL):** As VLDL loses its TGs, it becomes smaller and denser, transitioning into intermediate density lipoproteins (IDL).
5. **IDL Metabolism:** IDL can either be taken up by the liver through receptor-mediated endocytosis or further metabolized by hepatic lipase (HL).
6. **Formation of Low-Density Lipoproteins (LDL):** IDL that is not taken up by the liver is further metabolized by HL, leading to the formation of low-density lipoproteins (LDL). LDL is the primary carrier of cholesterol in the blood.
7. **LDL Uptake:** LDL particles are taken up by cells through receptor-mediated endocytosis, providing cholesterol for various cellular processes.
8. **Chylomicron Transport:** Dietary TGs are absorbed in the small intestine and packaged into chylomicrons, a type of lipoprotein similar to VLDL. Chylomicrons enter the lymphatic system and eventually reach the bloodstream. They also undergo LPL activity, releasing fatty acids for uptake by various tissues.
9. **Chylomicron Remnants:** After TG hydrolysis, chylomicron remnants are taken up by the liver for further processing.
The transport of TGs is a complex and highly regulated process. It involves the coordinated action of various enzymes, proteins, and receptors. Disruptions in TG transport can contribute to various health problems, including atherosclerosis, obesity, and type 2 diabetes.'
"
Protein | Definition | Taxonomy |
---|---|---|
Microsomal triglyceride transfer protein large subunit | A microsomal triglyceride transfer protein large subunit that is encoded in the genome of human. [PRO:HJD, UniProtKB:P55157] | Homo sapiens (human) |
Cholesteryl ester transfer protein | A cholesteryl ester transfer protein that is encoded in the genome of human. [PRO:DNx, UniProtKB:P11597] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
niacin | Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms). | pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3 | antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent |
nevirapine | nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection. Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS. | cyclopropanes; dipyridodiazepine | antiviral drug; HIV-1 reverse transcriptase inhibitor |
efavirenz | efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection. efavirenz: HIV-1 reverse transcriptase inhibitor | acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound | antiviral drug; HIV-1 reverse transcriptase inhibitor |
ursolic acid | hydroxy monocarboxylic acid; pentacyclic triterpenoid | geroprotector; plant metabolite | |
torcetrapib | (trifluoromethyl)benzenes; carbamate ester; quinolines | anticholesteremic drug; CETP inhibitor | |
sb 203580 | imidazoles; monofluorobenzenes; pyridines; sulfoxide | EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent | |
delta-8-tetrahydrocannabinol | 1-benzopyran | ||
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin | 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: structure in first source alvespimycin : A 19-membered macrocyle that is geldanamycin in which the methoxy group attached to the benzoquinone moiety has been replaced by a 2-(N,N-dimethylamino)ethylamino group. | 1,4-benzoquinones; ansamycin; carbamate ester; secondary amino compound; tertiary amino compound | Hsp90 inhibitor |
tanespimycin | CP 127374: analog of herbimycin A | 1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound; secondary amino compound | antineoplastic agent; apoptosis inducer; Hsp90 inhibitor |
dalcetrapib | dalcetrapib: inhibits cholesteryl ester transfer protein (CETP) | anilide | |
am-411 | |||
sc 795 | |||
3-((3-(4-chloro-3-ethylphenoxy)phenyl)(3-(1,1,2,2-tetrafluoroethoxy)benzyl)amino)-1,1,1-trifluoropropan-2-ol | 3-((3-(4-chloro-3-ethylphenoxy)phenyl)(3-(1,1,2,2-tetrafluoroethoxy)benzyl)amino)-1,1,1-trifluoropropan-2-ol: inhibits cholesteryl ester transfer protein; structure in first source | ||
bms201038 | BMS201038: an anticholesteremic agent and microsomal triglycide transfer protein inhibitor lomitapide : A member of the class of benzamides obtained by formal condensation of the carboxy group of 4'-(trifluoromethyl)biphenyl-2-carboxylic acid with the primary amino group of 9-[4-(4-aminopiperidin-1-yl)butyl]-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide. Used (as its mesylate salt) as a complement to a low-fat diet and other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia. | (trifluoromethyl)benzenes; benzamides; fluorenes; piperidines | anticholesteremic drug; MTP inhibitor |
dirlotapide | dirlotapide: structure in first source | ||
amg 3 | AMG 3: structure in first source | ||
km-233 | KM-233: used for the treatment of high-grade glioma; structure in first source | ||
mk 0354 | |||
anacetrapib | |||
gdc 0941 | pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring. | indazoles; morpholines; piperazines; sulfonamide; thienopyrimidine | EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor |
jnj-31020028 | |||
skepinone-l | skepinone-L: a dibenzosuberone-type p38 MAPK inhibitor; structure in first source | ||
evacetrapib | benzazepine |